[go: up one dir, main page]

LT3433238T - Prostatai būdingi membraniniai antigenai tiksliniai aukšto giminingumo agentai, skirti prostatos vėžio endoradioterapijai - Google Patents

Prostatai būdingi membraniniai antigenai tiksliniai aukšto giminingumo agentai, skirti prostatos vėžio endoradioterapijai

Info

Publication number
LT3433238T
LT3433238T LTEPPCT/US2017/023508T LTUS2017023508T LT3433238T LT 3433238 T LT3433238 T LT 3433238T LT US2017023508 T LTUS2017023508 T LT US2017023508T LT 3433238 T LT3433238 T LT 3433238T
Authority
LT
Lithuania
Prior art keywords
endoradiotherapy
prostates
prostate cancer
membrane antigens
target agents
Prior art date
Application number
LTEPPCT/US2017/023508T
Other languages
English (en)
Inventor
Sangeeta Ray
Martin G. Pomper
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of LT3433238T publication Critical patent/LT3433238T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/US2017/023508T 2016-03-22 2017-03-22 Prostatai būdingi membraniniai antigenai tiksliniai aukšto giminingumo agentai, skirti prostatos vėžio endoradioterapijai LT3433238T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662311697P 2016-03-22 2016-03-22
PCT/US2017/023508 WO2017165473A1 (en) 2016-03-22 2017-03-22 Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Publications (1)

Publication Number Publication Date
LT3433238T true LT3433238T (lt) 2021-09-27

Family

ID=59899817

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/023508T LT3433238T (lt) 2016-03-22 2017-03-22 Prostatai būdingi membraniniai antigenai tiksliniai aukšto giminingumo agentai, skirti prostatos vėžio endoradioterapijai
LTEP21177643.0T LT3925952T (lt) 2016-03-22 2017-03-22 Prostatai būdingi membraniniai antigenai tiksliniai aukšto giminingumo agentai, skirti prostatos vėžio endoradioterapijai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP21177643.0T LT3925952T (lt) 2016-03-22 2017-03-22 Prostatai būdingi membraniniai antigenai tiksliniai aukšto giminingumo agentai, skirti prostatos vėžio endoradioterapijai

Country Status (27)

Country Link
US (3) US11458213B2 (lt)
EP (3) EP3925952B1 (lt)
JP (3) JP7073270B2 (lt)
KR (4) KR102396307B1 (lt)
CN (3) CN114716387B (lt)
AU (1) AU2017238181B2 (lt)
BR (1) BR112018069507A2 (lt)
CA (1) CA3018709A1 (lt)
CL (1) CL2018002683A1 (lt)
CY (1) CY1124487T1 (lt)
DK (2) DK3925952T3 (lt)
ES (2) ES2972148T3 (lt)
FI (1) FI3925952T3 (lt)
HR (2) HRP20240215T1 (lt)
HU (2) HUE055607T2 (lt)
LT (2) LT3433238T (lt)
MX (1) MX384823B (lt)
PH (1) PH12018502048A1 (lt)
PL (2) PL3433238T3 (lt)
PT (2) PT3925952T (lt)
RS (2) RS62274B1 (lt)
RU (2) RU2021115958A (lt)
SA (1) SA518400103B1 (lt)
SI (2) SI3433238T1 (lt)
TR (1) TR201813644T1 (lt)
WO (1) WO2017165473A1 (lt)
ZA (1) ZA201806389B (lt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019002560B1 (pt) 2016-08-10 2022-08-16 Cancer Targeted Technology Llc Composto, composição farmacêutica, seus usos e método de preparação do mesmo
WO2018098390A1 (en) * 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
EP3494999A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Psma ligands for imaging and endoradiotherapy
EP3494998A1 (en) * 2017-12-11 2019-06-12 Technische Universität München Glycosylated psma inhibitors for imaging and endoradiotherapy
PT3723815T (pt) * 2017-12-11 2022-05-30 Univ Muenchen Tech Ligandos psma para imagiologia e endorradioterapia
IL275317B (en) 2017-12-13 2022-09-01 Sciencons AS A complex containing a compound against psma attached to a radioactive nucleus of lead or thorium
US11813340B2 (en) * 2018-02-06 2023-11-14 The Johns Hopkins University PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
MX2020008271A (es) * 2018-02-06 2020-11-09 Univ Heidelberg Inhibidor de fap.
HRP20230604T1 (hr) * 2018-03-30 2023-09-29 Futurechem Co., Ltd. Radiofarmaceutik usmjeren na psma, namijenjen dijagnosticiranju i liječenju raka prostate
CA3098492A1 (en) 2018-04-27 2019-12-19 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
US20210393809A1 (en) * 2018-09-28 2021-12-23 Universität Heidelbert Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
KR102403970B1 (ko) * 2018-12-27 2022-05-31 (주)퓨쳐켐 카르복시산이 도입된 psma-표적 화합물 및 그의 용도
BR112021026812A2 (pt) * 2019-07-02 2022-02-22 Advanced Accelerator Applications Italy Srl Ligantes de antígeno de membrana específico da próstata (psma) e usos dos mesmos
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
EP3993838A1 (en) * 2019-07-02 2022-05-11 Novartis AG Prostate specific membrane antigen (psma) ligands and uses thereof
RU2730507C1 (ru) * 2019-08-27 2020-08-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе
JP2023523235A (ja) * 2020-04-29 2023-06-02 ノバルティス アーゲー Ｐｓｍａ結合リガンドを放射標識するための方法及びそれらのキット
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022101352A1 (en) 2020-11-12 2022-05-19 Abx Advanced Biochemical Compounds Gmbh Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
JP2023550411A (ja) * 2020-11-19 2023-12-01 ノバルティス アーゲー 前立腺特異的膜抗原（ｐｓｍａ）リガンドの合成
MX2021005089A (es) * 2021-04-30 2022-11-01 Instituto Nac De Investigaciones Nucleares Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos.
CA3222172A1 (en) * 2021-06-17 2022-12-22 Mayo Foundation For Medical Education And Research Methods and materials for combining biologics with multiple chelators
KR20230050552A (ko) * 2021-10-07 2023-04-17 (주)퓨쳐켐 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물
CN118647415A (zh) 2022-02-09 2024-09-13 诺华股份有限公司 包含225锕标记的络合物和铋多价螯合剂的药物组合物
EP4637843A2 (en) * 2022-12-21 2025-10-29 Mayo Foundation for Medical Education and Research Methods and materials for combining biologics with multiple chelators
WO2025022285A2 (en) 2023-07-21 2025-01-30 Novartis Ag Psma-targeting radioligand treatment regimen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008269094B2 (en) 2007-06-26 2015-04-09 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
CN102272100B (zh) 2008-12-05 2016-08-17 分子制药洞察公司 用于抑制psma的锝-和铼-双(杂芳基)络合物及其使用方法
EP3222617B1 (en) 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
AU2012294639B2 (en) 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
EP3524277B1 (en) * 2011-11-30 2023-03-08 The Johns Hopkins University Psma-targeting compound and uses thereof
CN105025933B (zh) 2013-01-14 2019-03-26 分子制药洞察公司 三嗪类放射性药物和放射性显影剂
EP3415489A1 (en) * 2013-10-18 2018-12-19 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP2862857A1 (en) 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CA2950892C (en) * 2014-05-06 2023-10-24 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
PL3183236T3 (pl) 2014-08-24 2022-07-18 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma
US11420910B2 (en) * 2014-10-30 2022-08-23 Katholieke Universitet Leuven Methods for low temperature fluorine-18 radiolabeling of biomolecules
US11520472B2 (en) * 2015-09-24 2022-12-06 Mitutoyo Corporation Inspection program editing environment including integrated alignment program planning and editing features
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy

Also Published As

Publication number Publication date
KR20230147751A (ko) 2023-10-23
JP7073270B2 (ja) 2022-05-23
HUE055607T2 (hu) 2021-12-28
CN109311827B (zh) 2022-04-12
MX384823B (es) 2025-03-14
ES2972148T3 (es) 2024-06-11
DK3925952T3 (da) 2024-02-05
NZ746701A (en) 2024-12-20
JP2019519467A (ja) 2019-07-11
ES2877572T3 (es) 2021-11-17
DK3433238T3 (da) 2021-09-06
PT3433238T (pt) 2021-07-28
CN114716387B (zh) 2025-04-01
CL2018002683A1 (es) 2019-04-22
NZ786380A (en) 2025-05-02
SA518400103B1 (ar) 2022-03-20
WO2017165473A1 (en) 2017-09-28
SI3433238T1 (sl) 2021-11-30
KR20220063298A (ko) 2022-05-17
ZA201806389B (en) 2024-01-31
AU2017238181B2 (en) 2021-05-27
US11458213B2 (en) 2022-10-04
CN120172884A (zh) 2025-06-20
MX2018011519A (es) 2019-01-28
PL3433238T3 (pl) 2021-12-13
CA3018709A1 (en) 2017-09-28
JP2024050608A (ja) 2024-04-10
CN109311827A (zh) 2019-02-05
HUE065327T2 (hu) 2024-05-28
PH12018502048A1 (en) 2019-07-01
SI3925952T1 (sl) 2024-03-29
KR102396307B1 (ko) 2022-05-09
RU2018133693A3 (lt) 2020-04-22
EP3433238A1 (en) 2019-01-30
CY1124487T1 (el) 2022-07-22
KR20250057132A (ko) 2025-04-28
US20200155713A1 (en) 2020-05-21
FI3925952T3 (fi) 2024-02-13
RS65188B1 (sr) 2024-03-29
RU2021115958A (ru) 2021-07-12
EP4385981A1 (en) 2024-06-19
EP3925952B1 (en) 2023-11-29
PL3925952T3 (pl) 2024-04-22
RU2749399C2 (ru) 2021-06-09
JP2022116028A (ja) 2022-08-09
HRP20211386T1 (hr) 2021-12-10
TR201813644T1 (tr) 2018-11-21
LT3925952T (lt) 2024-01-25
HRP20240215T1 (hr) 2024-04-26
KR20180134918A (ko) 2018-12-19
US20250195700A1 (en) 2025-06-19
US20230015736A1 (en) 2023-01-19
PT3925952T (pt) 2023-12-13
RS62274B1 (sr) 2021-09-30
BR112018069507A2 (pt) 2019-01-29
EP3433238A4 (en) 2019-09-11
EP3433238B1 (en) 2021-06-16
AU2017238181A1 (en) 2018-10-18
CN114716387A (zh) 2022-07-08
RU2018133693A (ru) 2020-04-22
EP3925952A1 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
LT3433238T (lt) Prostatai būdingi membraniniai antigenai tiksliniai aukšto giminingumo agentai, skirti prostatos vėžio endoradioterapijai
CY1125243T1 (el) Μεθοδος για την παρασκευη μιας ενωσης διαρυλθειοϋδαντοϊνης
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
LT3183268T (lt) Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
MX384024B (es) Peptidos macrociclicos utiles como inmunomoduladores.
HUE050155T2 (hu) 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
IL258378A (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
DK3186244T3 (da) Dioxolananaloger af uridin til behandling af cancer
IL264443A (en) Methods of treating prostate cancer
IL265697B1 (en) Treatment of prostate cancer
DK3117216T3 (da) Fremgangsmåde til detektering af en solid tumor-cancer
EA201791391A1 (ru) Способы получения соединения диарилтиогидантоин
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
IL253920B (en) Antibodies targeting a galactan-based o-antigen of k. pneumoniae
IL281281A (en) Combination therapy for the treatment of prostate cancer
DK3344287T3 (da) Anti-survivin-antistoffer til cancerterapi
LT3518911T (lt) Rad1901, skirtas naudoti kiaušidžių vėžio gydymui
DK3464620T3 (da) Bestemmelse af genetisk prædisponering for aggressiv prostatakræft
HK1259764A1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
EP3423088A4 (en) IMMUNE-BASED CANCER THERAPY
TH1601003749A (th) แอนทิบอดีชนิดโมโนคลอนัลที่ทำให้เป็นกลาง แอนทิ-il-33 ของมนุษย์